Recent Updates
Recently added Catalysts

Bio-Techne Corp

TECHFDA catalysts, PDUFA dates & pipeline intelligence
$72.7
▼ -0.05 · -0.07%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full TECH financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $43.2052W HIGH $72.88
Volume
3.32 M
Value Traded
241.60 M
Short % Float
4.93%
Days to Cover
2.7
-0.19%Week
+0.17%1 Month
+0.58%3 Month
+53.47%6 Month
-53.43%5 Year
+43,977.71%All Time

Cash Data

Unlock TECH cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
11.42 B
EPS (TTM)
1.09
P/E Ratio
66.41
Ent. Value
11.27 B
Total Shares
157.06 M
Float Shares
156.22 M
Insiders
0.55%
Institutions
101.87%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every TECH catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

TECH Catalyst Timeline

Dated clinical, regulatory and corporate events for Bio-Techne Corp

Catalyst Timeline

Dated clinical, regulatory & corporate events for Bio-Techne Corp

455Total events
4Upcoming
97Tier-1 (high impact)
2014 to 2027Coverage

Upcoming catalysts 2

T2Timing Guidance
Subscribe to view catalyst details
T1Partnership / License
Subscribe to view catalyst details

Event history 50

●Corporate ApprovalCorporate
Bio-Techne board declares quarterly dividend of $0.08 per share
▲Manufacturing MilestoneCMC / Inspection
Opening of new GMP small molecule manufacturing facility in Bristol, UK
▲Corporate ApprovalCorporate
Bio-Techne shareholders approve acquisition by Merck KGaA
▲Corporate ApprovalCorporate
HSR waiting period for Merck KGaA/Bio-Techne transaction expired
●Quarterly UpdateCorporate
Bio-Techne reported Q4 FY2026 financial results
▲Product LaunchPost-Market
Launch of expanded R&D Systems AI-Engineered Designer Protein portfolio including FGF-4 Heat Stable, FGF-7 Heat Stable, FGF-8b Heat Stable, IL-3 Heat Stable, IL-15 Hyperactive
●Manufacturing MilestoneCMC / Inspection
Customer Experience Centre opening in Düsseldorf, Germany
▲AcquiredCorporate
Bio-Techne entered into agreement to be acquired by Merck KGaA
●Poster PresentationPresentation
Presentation of integrated workflow at ASMS conference
◆Oral PresentationPresentation
Bio-Techne to present at Bank of America Securities 2026 Global Healthcare Conference
Unlock the full TECH catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How TECH actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all TECH historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Unlock the TECH pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every TECH program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
metastatic melanoma2025-11-0442 pre-treatment biopsies, three treatment arms incorporating Immune Checkpoint Blockade (ICB)Read MoreAI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma PatientsRead More
Scroll for more · summaries link to the source press release
Unlock every TECH trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock TECH insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Hippel JamesOfficer (CFO)Option 11,545 181,816 held$0.00 11/01/2026
Unlock the full TECH insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
IRON TRIANGLE PARTNERS LP 3.1 % (34.8 %) 27.49 M 467.41 K 86.96% ( 217.41 K)
Unlock every fund holding TECH
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in TECH
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see TECH ownership
Insider and institutional ownership, quarter by quarter.

TECH Short Interest

Shares sold short, counted twice a month.

4.93%
Short % of Float
of tradable shares sold short
7.7M
Shares Sold Short
+2.0% vs prior count
2.7 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.8M
Avg Daily Volume
the average used for days to cover
Unlock TECH short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock TECH option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live TECH option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock TECH options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How TECH ranks across every disease it competes in

Competitive Position is a premium feature
See how TECH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

TECH News

TECH
Nov 4, 2026
TECHGeneral

BIO-TECHNE DECLARES DIVIDEND

Bio-Techne Corporation announced a quarterly dividend of $0.08 per share for Q3 2026. The dividend is payable on November 23, 2026, to shareholders recorded by November 13, 2026. This decision is contingent upon the completion of Bio-Techne's acquisition by Merck KGaA. Future dividends will be evaluated quarterly by the Board.

Read more →
TECH
Oct 8, 2026
TECHGeneral

Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development

Bio-Techne has opened a new GMP manufacturing facility in Bristol, UK, to enhance its capabilities in supporting the cell therapy market. This 10,000-square-foot facility features advanced cleanrooms designed for high-quality small molecule production. The investment aims to address manufacturing challenges in cell therapy, ensuring consistent and scalable processes for therapy developers.

Read more →
TECH
Sep 23, 2026
TECHGeneral

Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany

Bio-Techne shareholders have approved the acquisition by Merck KGaA, marking a significant step towards completing the merger. The transaction is expected to provide substantial cash value to shareholders and enhance the capabilities of both companies in life sciences. The acquisition is anticipated to close by late 2026 or early 2027, pending regulatory approvals.

Read more →
TECH
Sep 22, 2026
TECHGeneral

Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration

Bio-Techne has inaugurated a new Customer Experience Center in Düsseldorf, Germany, aimed at enhancing collaboration and innovation in the life sciences sector. This facility will serve as a regional hub for researchers and organizations in the DACH and EMEA regions, providing hands-on access to Bio-Techne's technologies and expertise. The center will host workshops and training programs, reinforcing Bio-Techne's commitment to supporting scientific excellence across Europe.

Read more →
TECH
Sep 1, 2026
TECHGeneral

Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals

Bio-Techne Corporation has made significant strides in its climate goals, achieving validation from the Science Based Targets initiative for its greenhouse gas reduction targets. The company reported a 49% reduction in Scope 1 and 2 emissions year-over-year and transitioned to 100% renewable electricity at its Minneapolis headquarters. Additionally, Bio-Techne aims for 81% of its suppliers to have science-based targets by fiscal year 2030.

Read more →
TECH
Aug 13, 2026
TECHGeneral

Bio-Techne Corrects Dividend Announcement

Bio-Techne Corporation corrected its dividend announcement, stating the shareholder of record date is August 24, 2026, instead of August 17. The company will pay a dividend of $0.08 per share for the quarter ended June 30, 2026, payable on August 28, 2026. All other details of the announcement remain unchanged.

Read more →
TECH
Aug 12, 2026
TECHGeneral

Bio-Techne Declares Dividend

Bio-Techne Corporation announced a quarterly dividend of $0.08 per share for shareholders of record on August 17, 2026. This dividend reflects the company's strong financial performance, having generated over $1.2 billion in net sales in fiscal year 2026. The company, celebrating its 50th anniversary, continues to empower scientific communities globally.

Read more →
TECH
Aug 12, 2026
TECHGeneral

Bio-Techne Releases Fourth Quarter Fiscal 2026 Results

Bio-Techne Corporation reported its financial results for the fourth quarter of fiscal 2026, highlighting a 3% increase in organic revenue and a significant improvement in GAAP EPS. The company is set to be acquired by Merck KGaA for $73 per share, which is anticipated to provide new opportunities for growth. Despite these positives, adjusted EPS saw a slight decline, and overall revenue remained flat for the year.

Read more →
TECH
Jul 8, 2026
TECHGeneral

Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio

Bio-Techne Corporation has expanded its R&D Systems AI-Engineered Designer Protein portfolio with new heat-stable and hyperactive proteins. These innovations aim to enhance reproducibility and performance in advanced cell culture and cell therapy workflows. The new proteins are designed to address challenges in scaling cell therapy from discovery to manufacturing, supporting various applications in regenerative medicine.

Read more →
TECH
Jun 25, 2026
TECHGeneral
▲ +20.1%on this news

Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets

Merck KGaA has agreed to acquire Bio-Techne for $73 per share, totaling $11.3 billion. This acquisition aims to enhance Merck's leadership in life sciences by integrating Bio-Techne's advanced technologies. The deal is expected to be accretive to sales growth and EBITDA margins, with significant cost synergies projected by year three.

Read more →
TECH
Jun 4, 2026
TECHConferences/Events

Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization

Bio-Techne and Refeyn announced an integrated workflow for characterizing bispecific antibodies and biosimilars. The system combines icIEF fractionation with mass photometry to analyze charge and size variants. This method completes analysis in four hours using only nanogram-level samples. The approach aims to reduce development risk and accelerate manufacturing processes.

Read more →
TECH
May 6, 2026
TECHGeneral
▼ -16.4%on this news

Bio-Techne Releases Third Quarter Fiscal 2026 Results

Bio-Techne Corporation reported its third quarter fiscal 2026 results, revealing a 2% decline in revenue to $311.4 million, impacted by prior-year orders and shipment timing. Despite this, GAAP EPS rose to $0.32, and large pharma continued its growth trend. The company remains optimistic about future demand as funding activity stabilizes.

Read more →
TECH
May 4, 2026
TECHConferences/Events

Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference

Bio-Techne Corporation announced that CEO Kim Kelderman will present at the Bank of America Securities 2026 Global Healthcare Conference on May 12, 2026. The presentation will be accessible via a live webcast on the company's Investor Relations website. Bio-Techne has a rich history of 50 years in the life sciences sector and operates globally.

Read more →
TECH
Apr 16, 2026
TECHGeneral

Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity

Bio-Techne Corporation has introduced a streamlined brand architecture to improve customer navigation of its life science solutions. The new structure organizes products into three focused brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, aligning with the progression of scientific research. This initiative aims to empower scientists and clinicians by providing easier access to essential tools and technologies.

Read more →
TECH
Apr 14, 2026
TECHConferences/Events

Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results

Bio-Techne Corporation announced a conference call scheduled for May 6, 2026, to discuss its third quarter fiscal 2026 financial results. The call will be accessible via dial-in and webcast, with a replay available for those unable to attend live. The company continues to thrive in the life sciences sector, generating significant revenue.

Read more →
TECH
Mar 25, 2026
TECHGeneral

Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite

Bio-Techne Corporation has expanded its COMET solution portfolio by introducing SPYRE Focus Panels and SPYRE Amplification Kits. These innovations aim to enhance the modular, automated spatial biology workflow, providing researchers with greater flexibility and sensitivity. The new features in HORIZON Image Analysis Software further support these advancements, facilitating deeper biological insights from tissue samples.

Read more →
TECH
Feb 24, 2026
TECHConferences/Events
▲ +5.2%on this news

Bio-Techne to Present at Upcoming Investor Conferences

Bio-Techne Corporation has announced its participation in two upcoming investor conferences. The TD Cowen 46th Annual Health Care Conference is scheduled for March 3, 2026, and the Leerink Partners Global Healthcare Conference will take place on March 10, 2026. Live webcasts of these presentations will be available on the company's Investor Relations website.

Read more →
TECH
Feb 16, 2026
TECHFDA Updates

Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories

Bio-Techne Corporation's Ella platform has received CE-IVD marking, allowing its sale in the European Union. This compact, cartridge-based immunoassay system provides rapid and accurate biomarker results, enhancing clinical workflows. The certification enables European laboratories to utilize Ella for in-house test development and clinical trials, supporting precision medicine initiatives.

Read more →
TECH
Feb 11, 2026
TECHGeneral

Bio-Techne Announces Changes to its Leadership Team

Bio-Techne Corporation announced a leadership change, with Dr. Matt McManus transitioning from his role as President of the Diagnostics and Spatial Biology Segment effective March 1, 2026. Steve Crouse, previously Senior Vice President of the Analytical Solutions Division, will take over as President. The transition aims to ensure continuity and leverage Crouse's extensive experience in the life sciences sector.

Read more →

About Bio-Techne Corp

Minneapolis, MN 3,000 employees bio-techne.com
Headquarters614 MCKINLEY PLACE NE, MINNEAPOLIS, MN
BIOPHARMAWATCH ELITE
Trade the next TECH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime